ReviewESC heart failure2023
Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients?
Review in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Guidelines on the Diagnosis and Treatment of Hypertrophic Cardiomyopathy - 2024.Arquivos brasileiros de cardiologia · 2024Guideline
- Cost-effectiveness analysis of mavacamten for obstructive hypertrophic cardiomyopathy: a perspective from the Chinese healthcare system.Open heart · 2026Article
- Mitral Valve Abnormalities as Predictors of Procedural Success in Alcohol Septal Ablation: A Pilot Study.Journal of clinical medicine · 2026Article
- Heart Failure in the Modern Era: A Narrative Overview of Recent Research from 2022-2025.Journal of cardiovascular development and disease · 2025Review
- Percutaneous endocardial septal radiofrequency ablation in patients with hypertrophic obstructive cardiomyopathy.BMC cardiovascular disorders · 2025Article
- Emergency Alcohol Septal Ablation for Cardiogenic Shock in Obstructive Hypertrophic Cardiomyopathy.JACC. Case reports · 2025Article
- Brazilian Multicenter Registry of Alcohol Septal Ablation for Patients with Symptomatic Hypertrophic Obstructive Cardiomyopathy - BRASA Registry.Arquivos brasileiros de cardiologia · 2025Article
- Left ventricular mechanics analysis after endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy.HeartRhythm case reports · 2025Article
- Systemic inflammation is associated with myocardial fibrosis in patients with obstructive hypertrophic cardiomyopathy.ESC heart failure · 2025Article
- Contrast echocardiography with a physiological contrast agent for alcohol septal ablation.Frontiers in cardiovascular medicine · 2025Article
- Influencing and prognostic factors of end-stage hypertrophic cardiomyopathy.ESC heart failure · 2024Article
- Exercise limitation in hypertrophic cardiomyopathy: combined stress echocardiography and cardiopulmonary exercise test.ESC heart failure · 2024Article
- Percutaneous endocardial septal radiofrequency ablation on syncope in patients with hypertrophic obstructive cardiomyopathy: a short-term safety and efficacy study.Annals of medicine and surgery (2012) · 2024Article
- The Clinical Impact of SARS-CoV-2 on Hypertrophic Cardiomyopathy.Journal of cardiovascular development and disease · 2024Article
- Short- and Mid-Term Outcomes of Early Alcohol Septal Ablation Therapy for Patients with Mildly Symptomatic Hypertrophic Obstructive Cardiomyopathy: A Tertiary Center Experience.Journal of clinical medicine · 2024Article
- Evolving indications for transcatheter mitral edge-to-edge repair.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2024Review
- Advances in Multi-Modality Imaging in Hypertrophic Cardiomyopathy.Journal of clinical medicine · 2024Review
- Clinical Effect of the Modified Morrow Septal Myectomy Procedure for Biventricular Hypertrophic Cardiomyopathy.Reviews in cardiovascular medicine · 2024Article
- Effects of bariatric surgery on cardiovascular-related acute care use in patients with hypertrophic cardiomyopathy.ESC heart failure · 2023Article
- Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients?ESC heart failure · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Percutaneous and surgical therapies for septal reduction for hypertrophic cardiomyopathy have been going head-to-head for the past 20 years with similar outcomes and mortality rates, although contemporary myectomy seems to materialize its superiority. However, on closer analysis, the external validity of studies advocating myectomy does not translate to all centres. The aim of this review was to examine the most recent data on septal reduction therapy and to attempt to phenotype the appropriate patient for each of the two treatments. The key to similar low mortality rates between ventricular septal myectomy and alcohol septal ablation appears to be proper patient selection performed in high volume clinical environments. Furthermore, we analyse the role of mavacampten (the recently approved cardiac myosin inhibitor) in replacing or complementing the two septal reduction therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.